Xencor, Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Xencor, Inc (XNCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2025-02-27
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- Xencor, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-02-27 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | 0.00% 10-K · filed 2025-02-27 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 0.00% 10-K/A · filed 2025-02-24 | |||
| 2020-12-31 | 0.00% 10-K · filed 2023-02-27 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2014-11-10 | |||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |